Protective and immunological behavior of chimeric yellow fever dengue vaccine

Vaccine

Volumn 34, Issue 14, 2016, Pages 1643-1647

  Halstead, Scott B ^a   Russell, Philip K ^a  

^a NONE   (United States)

Author keywords

Antibody dependent enhancement; Dengue; Dengue hemorrhagic fever; Efficacy; Flavivirus; Immunology; Protection; Vaccine

Indexed keywords

CHIMERIC YELLOW FEVER DENGUE VACCINE; DENGUE VACCINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY; YELLOW FEVER VACCINE;

CHILD HOSPITALIZATION; CLINICAL TRIAL (TOPIC); DENGUE; DISEASE SEVERITY; DRUG EFFICACY; EPIDEMIOLOGICAL DATA; HIGH RISK PATIENT; HUMAN; IMMUNE RESPONSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; WILD TYPE; ADOLESCENT; BLOOD; CHILD; HOSPITALIZATION; IMMUNOLOGY; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; STATISTICS AND NUMERICAL DATA; YELLOW FEVER;

ADOLESCENT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; DENGUE; DENGUE VACCINES; HOSPITALIZATION; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; YELLOW FEVER; YELLOW FEVER VACCINE;

EID: 84960349690     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.02.004     Document Type: Review

References (32)

1. Hadinegoro S.R., Arredondo-Garcia J.L., Capeding M.R., Deseda C., Chotpitayasunondh T., Dietze R., et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med 2015, 373:1195-1206.
2. Guy B., Jackson N. Dengue vaccine: hypotheses to understand CYD-TDV-induced protection. Nat Rev Microbiol 2016, 14:45-54.
3. Wilder-Smith A., Gubler D.J. PUBLIC HEALTH. Dengue vaccines at a crossroad. Science 2015, 350:626-627.
4. Sabchareon A., Wallace D., Sirivichayakul C., Limkittikul K., Chanthavanich P., Suvannadabba S., et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012, 380:1559-1567.
5. Capeding M.R., Tran N.H., Hadinegoro S.R., Ismail H.I., Chotpitayasunondh T., Chua M.N., et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 2014, 384:1358-1365.
6. Villar L., Dayan G.H., Arredondo-Garcia J.L., Rivera D.M., Cunha R., Deseda C., et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med 2014, 372:113-123.
7. Sabchareon A., Sirivichayakul C., Limkittikul K., Chanthavanich P., Suvannadabba S., Jiwariyavej V., et al. Dengue infection in children in Ratchaburi, Thailand: a cohort study I. Epidemiology of symptomatic acute dengue infection in children, 2006-2009. PLoS Negl Trop Dis 2012, 6:e1732.
8. Sangkawibha N., Rojanasuphot S., Ahandrik S., Viriyapongse S., Jatanasen S., Salitul V., et al. Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand I. The 1980 outbreak. Am J Epidemiol 1984, 120:653-669.
9. Endy T.P., Yoon I.K., Mammen M.P. Prospective cohort studies of dengue viral transmission and severity of disease. Curr Top Microbiol Immunol 2010, 338:1-13.
10. Endy T.P., Chunsittiwat S., Nisalak A., Libraty D., Green S., Rothman A., et al. Epidemiology of inapparent and symptomtic acute dengue virus infection: a prospective study of primary school children in Kamphaeng Phet Thailand. Am J Epidemiol 2002, 156:40-51.
11. Gordon A., Kuan G., Mercado J.C., Gresh L., Aviles W., Balmaseda A., et al. The nicaraguan pediatric dengue cohort study: incidence of inapparent and symptomatic dengue virus infections, 2004-2010. PLoS Negl Trop Dis 2013, 7:e2462.
12. Halstead S.B. Neutralization and antibody dependent enhancement of dengue viruses. Adv Virus Res 2003, 60:421-467.
13. Vaughn D.W., Green S., Kalayanarooj S., Innis B.L., Nimmannitya S., Suntayakorn S., et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 2000, 181:2-9.
14. Buchy P., Vo V.L., Trinh T.X., Glaziou P., Le T.T., Le V.L., et al. Secondary dengue virus type 4 infections in Vietnam. Southeast Asian J Trop Med Public Health 2005, 36:178-185.
15. Anderson K.B., Gibbons R.V., Thomas S.J., Rothman A.L., Nisalak A., Berkelman R.L., et al. Preexisting Japanese encephalitis virus neutralizing antibodies and increased symptomatic dengue illness in a school-based cohort in Thailand. PLoS Negl Trop Dis 2011, 5:e1311.
16. Guzman M.G., Kouri G., Bravo J., Valdes L., Vazquez S., Halstead S.B. Effect of age on outcome of secondary dengue 2 infections. Int J Infect Dis 2002, 6:118-124.
17. Guzman M.G., Kouri G., Valdes L., Bravo J., Alvarez M., Vazquez S., et al. Epidemiologic studies on dengue in Santiago de Cuba, 1997. Am J Epidemiol 2000, 152:793-799.
18. Guzman M.G., Alvarez A., Vazquez S., Alvarez M., Rosario D., Pelaez O., et al. Epidemiological studies on dengue virus type 3 in Playa municipality, Havana, Cuba, 2001-2002. Int J Infect Dis 2012, 16:e198-e203.
19. OhAinle M., Balmaseda A., Macalalad A.R., Tellez Y., Zody M.C., Saborio S., et al. Dynamics of dengue disease severity determined by the interplay between viral genetics and serotype-specific immunity. Sci Transl Med 2011, 3:114ra28.
20. Hubert B., Halstead S.B. Dengue 1 virus and dengue hemorrhagic fever, French Polynesia, 2001. Emerg Infect Dis 2009, 15:1265-1270.
21. Sabin A.B. Research on dengue during World War II. Am J Trop Med Hyg 1952, 1:30-50.
22. Cummings D.A., Iamsirithaworn S., Lessler J.T., McDermott A., Prasanthong R., Nisalak A., et al. The impact of the demographic transition on dengue in Thailand: insights from a statistical analysis and mathematical modeling. PLoS Med 2009, 6:e1000139.
23. Anders K.L., Nguyet N.M., Chau N.V., Hung N.T., Thuy T.T., Lien le B., et al. Epidemiological factors associated with dengue shock syndrome and mortality in hospitalized dengue patients in Ho Chi Minh City, Vietnam. Am J Trop Med Hyg 2011, 84:127-134.
24. Gibbons R.V., Kalanarooj S., Jarman R.G., Nisalak A., Vaughn D.W., Endy T.P., et al. Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences. Am J Trop Med Hyg 2007, 77:910-913.
25. Olkowski S., Forshey B.M., Morrison A.C., Rocha C., Vilcarromero S., Halsey E.S., et al. Reduced risk of disease during postsecondary dengue virus infections. J Infect Dis 2013, 208:1026-1033.
26. Guy B., Barrere B., Malinowski C., Saville M., Teyssou R., Lang J. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 2011, 29:7229-7241.
27. Coudeville L., Baurin N., Vergu E. Estimation of parameters related to vaccine efficacy and dengue transmission from two large phase III studies. Vaccine 2015, [Epub ahead of print]. 10.1016/j.vaccine.2015.11.023.
28. Shu P.Y., Chen L.K., Chang S.F., Yeuh Y.Y., Chow L., Chien L.J., et al. Comparison of capture immunoglobulin M (IgM) and IgG enzyme-linked immunosorbent assay (ELISA) and nonstructural protein NS1 serotype-specific IgG ELISA for differentiation of primary and secondary dengue virus infections. Clin Diagn Lab Immunol 2003, 10:622-630.
29. Chao D.Y., Galula J.U., Shen W.F., Davis B.S., Chang G.J. Nonstructural protein 1-specific immunoglobulin m and g antibody capture enzyme-linked immunosorbent assays in diagnosis of flaviviral infections in humans. J Clin Microbiol 2015, 53:557-566.
30. Halstead S.B., Rojanasuphot S., Sangkawibha N. Original antigenic sin in dengue. Am J Trop Med Hyg 1983, 32:154-156.
31. Midgley C.M., Bajwa-Joseph M., Vasanawathana S., Limpitikul W., Wills B., Flanagan A., et al. An in-depth analysis of original antigenic sin in dengue virus infection. J Virol. 2011, 85:410-421.
32. Dorigatti I., Aguas R., Donnelly C.A., Guy B., Coudeville L., Jackson N., et al. Modelling the immunological response to a tetravalent dengue vaccine from multiple phase-2 trials in Latin America and South East Asia. Vaccine 2015, 33:3746-3751.